ReviewBreast (Edinburgh, Scotland)2025
Improving the quality of life of people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (goal 3).
Review in Breast (Edinburgh, Scotland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.Breast cancer (Tokyo, Japan) · 2026Trial
- Article
- CDK4/6 Inhibitors for Breast Cancer Therapy-A Review of Clinical Trials, Structural and Computational Approaches.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Metastatic Recurrence of Breast Cancer by Stage and Molecular Profile: A Population-Based Study Among Italian Women.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress in the treatment landscape for advanced breast cancer (ABC) has significantly extended the survival of people with the disease. However, longevity alone is insufficient; maintaining and enhancing quality of life (QoL) is vital to ensure that people with ABC experience not only longer lives but fulfilling ones. Literature consistently highlights the unmet psychosocial needs of people with ABC, and its negative impact on QoL. Furthermore, many awareness and support programs disproportionately focus on early breast cancer, resulting in substantial gaps in information, resources, and medical and psychological support for people with ABC, which in turn can exacerbate feelings of isolation and stigma. This manuscript explores the impact of ABC on QoL and draws on research conducted for the development of the ABC Global Alliance's Global Decade Report 2.0. The main findings are: a) QoL improvements over the last decade vary between ABC subtypes, with triple negative ABC patients having the lowest QoL; b) The impact of ABC on QoL remains unequal between populations; c) Low-grade side effects of ABC treatment have a profound impact on QoL; d) ABC has a substantial impact on caregiver QoL; e) Many QoL assessment tools currently fail to capture the specific needs of people with ABC. The findings from the ABC Global Alliance's Global Decade Report 2.0 have informed the development of a new ABC Global Charter. The ABC Global Charter 2.0 defines ten new achievable and measurable goals for the decade 2025-2035, aiming at improving the lives of people living with ABC worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.